All In Biotech

NDA 213586 · Teva

Uzedy

Risperidone · Subcutaneous · Atypical Antipsychotic

Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Apr 28, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

514

127 Phase 3, 14 recruiting

FAERS reports

64,028

49,562 serious, 5,886 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for the treatment of patients with dementia-related psychosis and has not been studied in this patient population [see Warnings and Precautions ( 5.1 )]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for use in patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Oct 31, 2025.

UZEDY is an atypical antipsychotic indicated: for the treatment of schizophrenia in adults. ( 1.1 ) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. ( 1.2 ) 1.1 Schizophrenia UZEDY is indicated for the treatment of schizophrenia in adults . 1.2 Bipolar Disorder UZEDY is indicated as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder in adults.

Mechanism: The mechanism of action of risperidone, for the listed indications, is unclear. The drug’s therapeutic activity could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone (paliperidone) [see Clinical Pharmacology ( 12.3 )] . Antagonism at receptors other than D 2 and 5HT 2 may explain some of the other effects of risperidone.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 10, 2025 Supplement 8 · Efficacy LabelLetter
  • Apr 28, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
7 products under this application
  • UZEDY · RISPERIDONE 200MG/0.56ML (200MG/0.56ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • UZEDY · RISPERIDONE 125MG/0.35ML (125MG/0.35ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • UZEDY · RISPERIDONE 75MG/0.21ML (75MG/0.21ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • UZEDY · RISPERIDONE 250MG/0.7ML (250MG/0.7ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • UZEDY · RISPERIDONE 150MG/0.42ML (150MG/0.42ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • UZEDY · RISPERIDONE 100MG/0.28ML (100MG/0.28ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • UZEDY · RISPERIDONE 50MG/0.14ML (50MG/0.14ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Risperidone" as an intervention, any sponsor and status, largest first.

All 514 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • gynaecomastia9,330
  • off label use5,729
  • drug ineffective5,316
  • weight increased4,408
  • drug interaction3,245
  • product use in unapproved indication2,988
  • emotional disorder2,879
  • abnormal weight gain2,864
  • condition aggravated2,411
  • somnolence2,323
  • toxicity to various agents2,293
  • extrapyramidal disorder2,091

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004400
2005506
2006592
2007580
2008698
20091,200
20101,157
20111,587
20121,884
20131,528
20141,923
20154,815
20164,930
20176,885
20184,496
20194,735
20204,062
20213,694
20223,744
20233,527
20243,981
20253,972
20263,131

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Uzedy (Risperidone)

2024 spending

$65.3M

Beneficiaries

4,439

20,266 claims

Per beneficiary

$14,711

$9,293.89 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$9,765,799
2024$65,302,427

Part B: Uzedy (Risperidone) · HCPCS J2799

2024 spending

$100K

Beneficiaries

41

100 claims

Per beneficiary

$2,449

2024 ASP limit $24.74 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$100,391

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,258 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.